Based on the available evidence (12, 13), in the current eighth edition staging system of the AJCC, stage IIA-IIIA resectable NSCLC patients without EGFR mutations or ALK fusions are the target population for neoadjuvant chemotherapy in combination with immunotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.